SAN

97.74

-0.91%↓

223.6

+3.09%↑

MRK1

153.55

-0.71%↓

SHL.DE

48.11

-0.35%↓

ARGX

544.2

-1.13%↓

SAN

97.74

-0.91%↓

223.6

+3.09%↑

MRK1

153.55

-0.71%↓

SHL.DE

48.11

-0.35%↓

ARGX

544.2

-1.13%↓

SAN

97.74

-0.91%↓

223.6

+3.09%↑

MRK1

153.55

-0.71%↓

SHL.DE

48.11

-0.35%↓

ARGX

544.2

-1.13%↓

SAN

97.74

-0.91%↓

223.6

+3.09%↑

MRK1

153.55

-0.71%↓

SHL.DE

48.11

-0.35%↓

ARGX

544.2

-1.13%↓

SAN

97.74

-0.91%↓

223.6

+3.09%↑

MRK1

153.55

-0.71%↓

SHL.DE

48.11

-0.35%↓

ARGX

544.2

-1.13%↓

Kodu・Aktsiate loetelu・UCB SA

UCB SA

Suletud

Sektor Tervishoid

178.7 -0.97

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

177.55

Max

181.3

Põhinäitajad
By Trading Economics
Sissetulek	104M
Müük	127M 2.8B
P/E Sektori keskmine	26.67 104.138
Aktsiakasum	2.09
Kasumimarginaal	3.728

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+19.23 upside

Turustatistika
By TradingEconomics
Turukapital	598M 34B
Eelmine avamishind	179.67
Eelmine sulgemishind	178.7

Uudiste sentiment

By Acuity

64%

36%

339 / 390 Pingereas Healthcare

UCB SA Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

5. dets 2023, 16:47 UTC

Market Talk

European Pharmas With New Drugs Hold Most Promise in 2024 -- Market Talk

Võrdlus sarnastega

Hinnamuutus

UCB SA Prognoos

Hinnasiht

By TipRanks

19.23% tõus

12 kuu keskmine prognoos

Keskmine 94.86 EUR 19.23%

Kõrge 125 EUR

Madal 74 EUR

Põhineb 7 Wall Streeti analüütiku instrumendi UCB SA 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

7 ratings

Osta

Hoia

Müü

Põhineb 7 analüütiku instrumendi UCB SA aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

339 / 390 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

EBITDA

Ärikasum

Ettevõttest UCB SA

Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.